Status:
RECRUITING
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborating Sponsors:
McMaster University
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Detailed Description
GAIN PC CONTROL is an open-label single-arm phase IV trial that will evaluate 1) the safety and tolerability of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in men with prostate cancer (PC) t...
Eligibility Criteria
Inclusion
- Have a physician diagnosis of PC
- Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor)
- Elevated BMI
- ≥30kg/m2 or
- ≥27kg/m2 in the presence of at least one of hypertension, type 2 diabetes, obstructive sleep apnea or dyslipidemia
Exclusion
- Type 1 diabetes
- Taking a GLP-1 RA
- \<18 years of age
- History of pancreatitis
- Personal or family history of medullary cancer of the thyroid
- Multiple endocrine neoplasia type 2
Key Trial Info
Start Date :
July 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06908694
Start Date
July 2 2025
End Date
July 31 2026
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V1C3